Announced

Completed

Asahi Kasei completed the acquisition of Calliditas Therapeutics for $1.1bn.

Synopsis

Asahi Kasei, a multinational Japanese chemicals company, completed the acquisition of Calliditas Therapeutics, a commercial stage biopharmaceutical company, for $1.1bn.

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Asahi Kasei completed the acquisition of Calliditas Therapeutics for $1.1bn.